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OBJECTIVES: The FRAX® model recently developed by the WHO calculates 10-year 
probability of major osteoporotic and hip fracture, offering new basis for medical 
decision making and health economic analysis in osteoporosis (OP). [http://www.shef.
ac.uk/FRAX/]. Patients’ ideas regarding fracture risk and longevity might inﬂ uence 
their perception of 10-year fracture risk data and compliance, and as a consequence, 
successful implementation of FRAX® based thresholds in everyday OP care. Our aim 
was to study whether FRAX® data differ from OP patients’ and attendant especialists’ 
self-estimations on fracture risk. We also assessed expectations on longliving which is 
a crucial point to perceive the 10-year farcture risk projection of FRAX® relevant. 
METHODS: In 2009 a cross-sectional survey was performed in 10 Hungarian rheu-
matology centres. Postmenopausal OP patients appearing on routine visit and switch-
ing to second line antiporotic drug were involved. Demographics, main clinical 
characteristics were registered. Patients’ estimation on 10-year fracture risk and 
longliving were surveyed. Physicians’ expectations on patients’ perspectives were likely 
detected. FRAX® was calculated and matched with the estimations. RESULTS: 224 
patients were involved, mean(SD): age 69.5(8.9)years, duration of OP care 6.7(5.1)
years, lumbar Tsc-3.17(0.82), femoral Tsc-2.69(0.87), 133(59.4%) patients had OP 
fracture previously. Health status VAS was 59(17)mm. FRAX®-major OP fracture 
was 26(15.7)%, patients estimated 32.7(25.8)%, physicians marked 29.9(21.4)%. 
Results for hip fracture were: FRAX® 12.6(15.3)%, patients 26.7(25.3)%, physicians 
21.5(19.1)% (P < 0.01). Patients’ expected to live until age 82.4(8.2)years, physicians’ 
estimation was nearly same (82.5, SD7 yrs). Less than 10-year survival was expected 
by 42,4% and 33.7%, respectively. CONCLUSIONS: Both patients and physicians 
overestimate fracture risk, especially for hip. Patients often expect to live shorter than 
the time-frame of the fracture risk projection. These aspects should be highly consid-
ered in health communication and also in the application of the FRAX® method in 
clinical practice.
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OBJECTIVES: Rheumatoid Arthritis (RA), a chronic inﬂ ammatory disease, may pre-
dispose to the development of Type 2 Diabetes Mellitus (T2DM). We aimed to 
compare incidence rates of T2DM in RA versus non-RA populations and study the 
inﬂ uencing factors. METHODS: The study population consisted of participants in the 
National Data Bank for Rheumatic Diseases (NDB), where patients with rheumato-
logic disorders completed semiannual questionnaires, from 1998 through 2008. 
Osteoarthritis (OA) patients were used as controls. T2DM was determined based on 
self-reports of disease and on the use of hypoglycemic medication. The association 
between RA and T2DM was investigated using COX logistic regressions adjusted for 
relevant clinical and demographic covariates. RESULTS: A total of 14,481 partici-
pants diagnosed with RA (79.5% female; mean age 58.1 years) and 3,441 participants 
diagnosed with OA (84.5% female; mean age 63.6 years) were followed during 69,943 
person-years. RA subjects had lower Body Mass Index (BMI) and less major comor-
bidities than controls. In patients with RA the T2DM incidence rate was 10 per 1000 
person-years, while the incidence rate for OA was 15 per 1000 person-years. Both 
rates are superior to most estimates calculated among the US population. However, 
the covariate-adjusted risk of T2DM in patients with RA versus OA was not signiﬁ cant 
(HR = 0.94; 95% CI: 0.79–1.12, p = NS). Male gender, age, BMI, non-caucasian 
ethnicity, major comorbidities, low education level and prednisone intake were sig-
niﬁ cantly associated with the incidence of T2DM. Some RA drugs had a clear protec-
tive role on TDM2, mainly methotrexate (19% risk reduction; p = 0.022) and 
hydroxicloroquine (47% risk reduction; P < 0.001). CONCLUSIONS: RA per se is 
not associated with increased risk of T2DM. Both RA and OA are associated with 
known TDM2 risk factors, such as BMI and some comorbidities, increasing the 
incidence rates of TDM2. Some drugs for RA treatment have a signiﬁ cant protective 
effect on the TDM2 risk.
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OBJECTIVES: Total knee replacement (TKR) is a commonly used surgical procedure 
for patients with severe joint damage caused by arthritis; however, there remain dif-
ﬁ culties in establishing criteria to deﬁ ne the optimal timing for TKR. The aim of this 
study was to identify the preoperative threshold HRQoL scores that were associated 
with better postoperative outcomes and those associated with greater improvement. 
METHODS: Data were collected from 1715 patients undergoing TKR between 2001 
and 2006. Patients were interviewed at baseline and at 6 months and 2 years after 
surgery. At all three interview sessions, patients were asked to complete the Short-
Form (SF-36) and the Oxford Knee Score (OKS). As physical function and pain have 
been identiﬁ ed as the key domains in osteoarthritis, the OKS and the physical function-
ing (PF) and bodily pain (BP) scales of the SF-36 were selected as the outcome measures 
of this study. Summary statistics were computed for preoperative, postoperative, and 
improvement in outcome scores. Visual inspection of the simple error bar charts were 
used to identify the threshold preoperative scores that were associated with better 
postoperative scores and those associated with more improvement. RESULTS: 
Patients with poorer preoperative HRQoL had worse postoperative outcomes but 
experienced greater improvement after TKR compared to those with better preopera-
tive HRQoL. The highest postoperative PF scores are associated with a preoperative 
PF score of 50 points and above, whereas the baseline threshold OKS score was 
between 35 and 40 points. a baseline PF score of <30 points and an OKS score of 
>40 points are associated with the greatest improvement. No clear leveling off pattern 
was observed in the BP scores. CONCLUSIONS: PF and OKS threshold scores associ-
ated with optimal outcomes of TKR were identiﬁ ed in this study. Future research is 
needed to examine the predictive value of the scores identiﬁ ed in improving patients’ 
post-operative outcomes.
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OBJECTIVES: To examine health-related quality of life (HRQoL) following total knee 
replacement (TKR) or unicompartmental knee arthroplasty (UKA). METHODS: 
Asian adult patients undergoing either TKR or UKA in a hospital of Singapore 
between 2001 and 2006 were interviewed before surgery and 6 and 24 months post-
operatively to obtain demographic information and HRQoL scores using the Short-
Form (SF-36) and the Oxford Knee Score (OKS). RESULTS: Data were collected from 
2243, 1715, and 1113 patients at baseline, 6, and 24 months, respectively. TKR 
patients had a lower preoperative score than UKA patients on OKS and four subscales 
of the SF-36 (p < 0.01). Both TKR and UKA patients’ OKS and SF-36 subscale scores 
improved six months postoperatively except in the general health domain. SF-36 role 
physical (RP) and bodily pain (BP) scores showed the most improvement (40.9 and 
33.0 points in TKR and 36.9 and 31.4 points in UKA patients, respectively). The most 
substantial improvements between baseline and two years after surgery were in the 
physical domains of HRQoL (RP, BP, and physical functioning (PF)). In addition, in 
both groups, ﬁ ve domains of SF-36 (RP, BP, PF, social functioning, and role limitations 
due to emotional problems) reached the proposed minimal clinically important differ-
ence of ten points. TKR patients’ SF-36 and OKS scores were not signiﬁ cantly different 
from those of UKA patients two year after surgery, except PF scores. Multiple regres-
sion analysis adjusting for sociodemographics showed that baseline scores were a 
signiﬁ cant predictor of the postoperative scores of OKS and all SF-36 subscales (p < 
0.01), whereas the type of surgery was not associated with the postoperative scores. 
CONCLUSIONS: Both TKR and UKA patients experienced signiﬁ cant improvements 
in HRQoL, particularly in the RP and BP domains. After controlling for potential 
confounding variables, the type of surgery was not a signiﬁ cant predictor of patients’ 
postoperative HRQoL scores.
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OBJECTIVES: To describe back pain, and HRQoL in postmenopausal women with 
osteoporosis treated with teriparatide (Forsteo®) in France. METHODS: European, 
prospective, observational study of 36 months duration (18-month active treatment 
phase and 18-month post-treatment follow up) in postmenopausal women with osteo-
porosis who initiated teriparatide. HRQoL measured by EQ-5D and back pain mea-
sured by a Visual Analogue Scale (VAS) and a questionnaire were collected at each 
follow-up visit. RESULTS: Among 309 patients enrolled in France (18.8% of the total 
EFOS cohort), 290 (94.5%) had any follow-up data, and 201 (65.0%) completed the 
last post-treatment visit. At baseline, patients were 73.8 (7.4) years old (mean (SD)), 
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98.6% of patients had 2 or more fractures after age 40 years, the mean (SD) number 
of fractures was 4.2 (1.7) and median number was 4.0 (interquartile range 3.0–5.0). 
During the study, the mean (SD) duration of treatment by teriparatide was 443 (203) 
days; at the end of 17th month, 67.9% of patients were still on treatment. The main 
reasons of treatment discontinuation were treatment completion (69.9%), adverse 
events (14.5%), patient decision (14.0%), and physician decision (2.2%). Between 
baseline and end of study, the rate of women with back pain decreased from 93.8% 
to 83.3% and 57.1% had an improvement in the severity, mean (SD) back pain 
intensity VAS decreased from 55.9 (24.8) to 35.0 (24.2), and mean (SD) EQ-5D VAS 
increased from 52.6 (19.4) at baseline to 57.8 (21.4) at end of study. CONCLUSIONS: 
French patients with severe osteoporosis treated with teriparatide in a routine setting 
had an increase in quality of life and a decrease in back pain during the teriparatide 
treatment period and post-treatment follow-up. The results should be interpreted in 
the context of a non-controlled observational study.
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BACKGROUND: The prevalence of sleep disturbances and fatigue among patients 
with rheumatoid arthritis (RA) is high. TNF therapy reduces disease activity and dis-
ability in RA, but few studies have analyzed the impact of TNF vs. traditional 
DMARD therapy, sociodemographic and clinical factors on sleep and fatigue, in 
prospective cohorts. OBJECTIVES: We assessed the effect of TNF therapy, sociode-
mographic and clinical factors on sleep disturbances and fatigue in RA patients. 
METHODS: A total of 1,082 RA patients from the NDB-Portugal cohort participated 
in this prospective study. Patients´ last observation was used. Univariate (UV) and 
multivariate (MV) linear regression models (β, 95% CI) assessed the impact of the 
following on sleep disturbances (measured by the sleep disturbance scale (VAS 0–10, 
10 is worst) and the insomnia severity index (0–28, 28 is worst)) and fatigue (fatigue 
scale (VAS 0–10,10 is worst)): traditional DMARD and TNF therapy, age, sex, educa-
tion level, marital status, number of major comorbidities, RA duration, disability 
(HAQ 0–3, 3 is worst), quality of life (VASQOL 0–1, 1 is better), emotional distress 
(Hospital Anxiety and Depression Scale—HADS 0–21, 21 is worst) and prednisone 
use. RESULTS: In MV, TNF therapy seemed to decrease fatigue (−0.60 (−1.08, −0.11)) 
when compared to traditional DMARDs and although not statistically signiﬁ cant, 
decreased sleep disturbances (−0.46 (−1.04, 0.13)) and insomnia (−0.22 (−1.16, 0.73)). 
An increase in sleep disturbances was seen with worse HAQ (0.64 (0.25, 1.02)), lower 
VASQOL: (−1.46 (−2.63, −0.28)), more anxiety symptoms: (0.19 (0.09, 0.29)) and 
higher fatigue (0.26 (0.17, 0.36)). These results were also seen for insomnia and 
fatigue. More sleep disturbances (0.18 (0.12, 0.25)) increased fatigue and higher 
fatigue increased insomnia (0.39 (0.23, 0.54)). CONCLUSIONS: We found that the 
use of TNF therapy improved fatigue when compared to traditional DMARDs. Higher 
disability and worse quality of life increased sleep disturbances, insomnia and fatigue.
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OBJECTIVES: Many studies have identiﬁ ed predictors of the health assement ques-
tionnaire (HAQ), but few have evaluated the predictors of HAQ trends among RA 
patients. To investigate the predictors of worsening disability trends compared to other 
patterns among RA patients over at least 2 years. METHODS: A total of 646 RA 
patients from the ongoing biannual NDB-Portugal cohort with at least four consecu-
tive HAQ scores per patient during their follow-up were used.The proportion deﬁ ned 
by the number of 6-month positive increments in HAQ scores (worsening function) 
divided by the total number of differences was computed per patient and used to deﬁ ne 
a patient’ trend. The outcome was then deﬁ ned as the presence of a trend of worsening 
disability (when proportion >0.5). This meant that a patient’s tendency of worsening 
was higher than their tendency of improving during their own follow-up. Univariate 
(UV) and multivariate (MV) generalized estimating equations (GEE) were used to 
study the predictors of a worsening disability trend. Age, education, disease duration, 
paid work, retirement, number of total major comorbidities, SF-36 mental component, 
RADAI, the VAS scales of sleep, fatigue and pain, the use of current TNF (with or 
without concomitant DMARDs) vs. traditional DMARD therapy and steroids, were 
used as possible predictors. RESULTS: A total of 26% patients had worsening dis-
ability trends. The UV analyses showed that all of the following factors were statisti-
cally relevant: age, educational level, number of major comorbidities, sleep disturbances 
and fatigue, RADAI and the use of TNF therapy. The ﬁ nal MV model included pain 
(OR: 1.003 (95%CI: (1.000; 1.005))), age (OR: 1.02 (1.01; 1.02)) and the use of TNF 
(OR: 0.94 (0.91; 0.97)). CONCLUSIONS: In our study, we showed that older age 
and more pain predicted worsening HAQ disability trends. The use of TNF therapy 
was the only factor that decreased the odds of having a worsening HAQ trajectory.
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RELATING OSTEOARTHRITIS AFFECTATION, FUNCTIONAL 
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OBJECTIVES: To establish a conceptual model which relates osteoarthritis (OA) 
affectation, functional disability in daily activities, and Quality of Life (QoL). 
METHODS: The present is an observational, cross-sectional, multicenter study. OA 
presence/absence, by location, was clinically recorded. Disability was assessed with 
the Health Assessment Questionnaire Disability Index (HAQ-DI), QoL through the 
EuroQoL-5D questionnaire. Descriptives were used for sociodemographic and clinical 
variables; relationship between OA, disability and QoL was estimated through Struc-
tural Equation Modeling (SEM). This multivariate analysis technique allows to 
hypothesize multiple relationships among latent, unobserved variables and tests the 
model with a equation system. RESULTS: A total of 965 OA patients were included 
[mean age = 64 years (SD = 11); 75% women]. Mean body locations affected by OA 
was 2.81 (median = 2; SD = 1.613). The most frequently affected locations were knees 
(67% of the patients), lumbar (60%) and cervical (45%) spine. Regarding EuroQoL-
5D, most patients reported not having severe problems in the ﬁ ve areas assessed. 
‘Other activities’ (mean = 1.172; SD = 0.957) and ‘reach’ (mean = 1.127; SD = 0.912) 
were the HAQ-DI categories that showed higher disability. The SEM presented OA, 
disability and QoL as latent, related variables. 92% of QoL was accounted for dis-
ability (R-squared = 0.92). The global model that depicts OA as causing disability, 
and disability affecting QoL, has a marginal adjustment (CMIN/DF = 5.42; RMR = 
0.026; RMSEA = 0.069). CONCLUSIONS: With the available data, the functional 
disability can account for the decrease in QoL. Theoretically, OA is strongly related 
with disability and QoL, but the model fails to fully explain this link. As statistical 
techniques need good measurement models to correctly estimate relationships, stan-
dard clinical records seem insufﬁ cient for this purpose. Additional valid measurements 
of OA affectation would be needed, to give evidence of its direct effect on disability 
and QoL.
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OBJECTIVES: To evaluate the impact of certolizumab pegol (CZP) monotherapy on 
household work and daily activities in RA patients over 2 years. METHODS: Patients 
in the FAST4WARD Phase III trial were randomised to CZP 400 mg administered 
every 4 weeks (Q4W) or placebo for 24 weeks. Those who completed or withdrew 
at/after Week 12 were eligible to enter an open-label extension (OLE) study of CZP 
400 mg Q4W. This analysis focuses on CZP completers who entered the OLE study 
and had 2 years (100 weeks) of CZP exposure from baseline (BL). Household pro-
ductivity and impact on family/social/leisure activities were assessed using the vali-
dated Work Productivity Survey (WPS-RA). Analyses were conducted on observed 
data. FAST4WARD:NCT00548834; OLE:NCT00160693. RESULTS: Sixty-nine 
CZP completers entered the OLE. At BL: mean disease duration: 9.5 years; mean 
HAQ-DI: 1.42; mean DAS28-3(CRP): 5.76. Burden of RA on household productivity 
at BL was substantial: mean 10.1 household work days missed/month, mean 12.1 
household work days with reduced productivity/month, mean 5 days missed/month 
of family/social/leisure activities. At Week 100, compared with BL, patients receiving 
CZP monotherapy reported on average fewer household work days missed per month 
(1.0 vs. 10.1), fewer days with reduced productivity in the home (1.1 vs. 12.1), reduced 
interference of RA on household productivity (2.0 vs. 5.8 on a 0–10 scale), fewer 
missed days of family/social/leisure activities (0.3 vs. 5.0). Improvements were seen as 
early as Week 4 and were sustained until Week 100. Over 12, 52 and 100 weeks, 
mean annualised cumulative gains from BL were 20.5, 108.4 and 199.3 household 
work days, respectively, 25.1, 136.0 and 244.9 more productive days within the 
household, and 11.9, 57.7 and 107.2 days gained of family/social/leisure activities. 
CONCLUSIONS: CZP 400 mg Q4W monotherapy provides sustained improvement 
in productivity within the home and in RA patients’ abilities to engage in family/social/
leisure activities. 
